Download Konstantopoulou CV B..

BIOGRAPHICAL SKETCH
NAME
POSITION TITLE
Special Scientific Personnel
Irene Konstantopoulou
Molecular Diagnostics Laboratory
National Center of Scientific Research “Demokritos”
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION
Bachelor in Biology, Aristotle University of
Thessaloniki, Greece (Prof. S.G. Scouras)
DEGREE
(if
applicable)
YEAR(s)
Bachelor
10/85-2/90
Biology
09/94-12/94
Molecular Biology
Post-graduate fellow (‘Erasmus’ scholarship) in the
Cell & Molecular Biology Unit, University Hospital,
University of Umea, Sweden (Dr. P. Sideras)
Ph.D. in Biology, Aristotle University of Thessaloniki,
Greece (Prof. S.G. Scouras)
PhD
10/1991-2/1997
Post-doctoral work, Biology Department, Aristotle
University of Thessaloniki, Greece (Prof. S.G.
Scouras)
Post-Doc
2/1997-5/1998
Post-doctoral fellow, Molecular Diagnostics Lab,
NCSR ‘Demokritos’, Athens, Greece (Dr. D.
Yannoukakos)
Post-Doc
5/1998-6/2004
FIELD OF STUDY
Molecular Biology &
Genetics (heat-shock
genes, molecular
evolution)
Molecular Biology &
Genetics (heat-shock
genes, molecular
evolution)
Molecular Genetics
(hereditary cancer
syndromes)
NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the
attached sample.
A. Positions and Honors. List in chronological order previous positions, concluding with your present position. List
any honors. Include present membership on any Federal Government public advisory committee.
6/04-5/05 Lab director, “BioGenomica - Center for Genetic Testing & Analyses S.A.”, a NCSR ‘Demokritos’ spin-off
company (Technological Park of Attica “Lefkippos”)
6/05-3/07 Postdoctoral Research Associate, Molecular Diagnostics Laboratory, NCSR “Demokritos”
3/07-today Research Scientist, Molecular Diagnostics Laboratory, NCSR “Demokritos”
Awards-Fellowships
2001 “Best Investigator” Award, 1st Congress of the World Society for Breast Cancer (Istanbul, Turkey)
2001 “Best Presentation”, 5th International Congress of the Hellenic Society for Breast Cancer Research, Hellenic
Anticancer Society
2003 1st Presentation Award, 8th Panhellenic Congress of the Greek Society of Mastology (Thessaloniki, Greece)
2000 Athens Medical Society, “Sotiris Papastamatis” Award.
1994 Erasmus student scholarship, European Commission
1992-1997 Special Postgraduate Scholarship (EMY), Aristotle University of Thessaloniki
Page 1
Biographical Sketch Format Page
B. Selected Peer-reviewed publications (in chronological order).
1. Konstantopoulou I, Kroupis C, Ladopoulou A, Pantazidis A, Boumba D, Lianidou ES, Petersen MΒ, Florentin
L, Chiotellis E, Nounesis G, Efstathiou E, Skarlos D, Tsionou C, Fountzilas G, Yannoukakos D “BRCA1
mutation analysis in breast/ovarian cancer families from Greece” Human Mutation (2000) 16(3): 272-273
2. Armakolas A, Ladopoulou Α, Konstantopoulou Ι, Gomatos IP, Kataki A, Konstadoulakis MM, Stathopoulos GP,
Markopoulos C, Leandros E, Gogas I, Yannoukakos D, Androulakis G “Mutations in the BRCA2 gene in Greek
breast cancer patients: determination of three novel mutations” Human Mutation (2002) 19(1): 81-82
3. Ladopoulou Α, Konstantopoulou Ι, Armaou S, Efstathiou E, Mihalatos M, Bardi G, Nasioulas G, Pandis N,
Yannoukakos D “A change in the last base of BRCA1 exon 23, 5586G>A, results in abnormal RNA splicing”
Cancer Genetics & Cytogenetics (2002) 134(2): 175-177
4. Ladopoulou Α, Kroupis C, Konstantopoulou I, Pantazidis A, Armaou S, Tsiagas I, Lianidou E, Efstathiou E,
Tsionou C, Panopoulos C, Mihalatos M, Nasioulas G, Fountzilas G, Pandis N, Yannoukakos D “Germ line
BRCA1 & BRCA2 mutations in Greek breast/ovarian cancer families. 5382insC is the most frequent mutation
observed” Cancer Letters (2002) 185(1): 61-70 - IMPACT FACTOR: 2.346
5. Tsoli E, Zacharatos P, Dasiou-Plakida D, Peros J, Evangelou C, Zavras AI, Yannoukakos D, Konstantopoulou
I, Asimakopoulos PJ, Kittas C, Gorgoulis VG “Growth index is independent of microvessel density in non-small
cell lung carcinomas” Human Pathology (2002) 33(8): 812-818 - IMPACT FACTOR: 3.029
6. Armaou S, Konstantopoulou I, Razis E, Boukovinas I, Xenidis N, Fountzilas G, Yannoukakos D “Genomic
rearrangements account for 5% of the BRCA1 mutations in Greek breast/ovarian cancer families;
identification of a novel genomic rearrangement in BRCA1 gene involving exon 24 and 3’ UTR” European
Journal of Cancer (2007) 43(2): 443-453 - IMPACT FACTOR: 4.167
7. Fostira F, Thodi G, Konstantopoulou I, Sandaltzopoulos R, Yannoukakos D “Hereditary cancer syndromes”
Journal of BUON (2007) Suppl 1: S13-S22
8. Konstantopoulou I, Rampias T, Ladopoulou A, Koutsodontis G, Armaou S, Anagnostopoulos T, Nikolopoulos
G, Kamakari S, Nounesis G, Stylianakis A, Karanikiotis C, Razis E, Gogas H, Keramopoulos A, Gaki V,
Markopoulos C, Skarlos D, Pandis N, Bei T, Arzimanoglou I, Fountzilas G, Yannoukakos D “Greek BRCA1 &
BRCA2 mutation spectrum: Two BRCA1 mutations account for half the carriers found among Greek high-risk
breast/ovarian cancer patients” Breast Cancer Research & Treatment (2008) 107(3) : 431–441
9. Anagnostopoulos T, Pertesi M, Konstantopoulou I, Armaou S, Kamakari S, Nasioulas G, Dobrovic A, Young
MA, Mitchell G, Fountzilas G, Yannoukakos D “A novel BRCA1 founder mutation G1738R related to breastovarian cancer predisposition, found in Greek patients” Breast Cancer Research & Treatment (2008) 110(2):
377-385 -
10.Armaou S, Pertesi M, Fostira F, Thodi G, Athanasopoulos PS, Kamakari S, Athanasiou A, Gogas
H, Yannoukakos D, Fountzilas G, Konstantopoulou I. Contribution of BRCA1 germ-line mutations to breast
cancer in Greece: a hospital-based study of 987 unselected breast cancer cases. Br J Cancer. 2009 Jul
7;101(1):32-7.
11.Sinilnikova OM, Antoniou AC, Simard J, Healey S, Léoné M, Sinnett D, Spurdle AB, Beesley J, Chen X;
kConFab, Greene MH, Loud JT, Lejbkowicz F, Rennert G, Dishon S, Andrulis IL; OCGN, Domchek SM,
Nathanson KL, Manoukian S, Radice P, Konstantopoulou I, Blanco I, Laborde AL, Durán M, Osorio A, Benitez
J, Hamann U, Hogervorst FB, van Os TA, Gille HJ; HEBON, Peock S, Cook M, Luccarini C, Evans DG, Lalloo
F, Eeles R, Pichert G, Davidson R, Cole T, Cook J, Paterson J, Brewer C; EMBRACE, Hughes DJ, Coupier I,
Giraud S, Coulet F, Colas C, Soubrier F, Rouleau E, Bièche I, Lidereau R, Demange L, Nogues C, Lynch HT;
GEMO, Schmutzler RK, Versmold B, Engel C, Meindl A, Arnold N, Sutter C, Deissler H, Schaefer D,Froster
UG; GC-HBOC, Aittomäki K, Nevanlinna H, McGuffog L, Easton DF, Chenevix-Trench G, Stoppa-Lyonnet D;
Consortium of Investigators of Modifiers of BRCA1/2. The TP53 Arg72Pro and MDM2 309G>T polymorphisms
are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. Br J Cancer. 2009 Oct
20;101(8):1456-60.
12. Engel C, Versmold B, Wappenschmidt B, Simard J, Easton DF, Peock S, Cook M, Oliver C, Frost D, Mayes
R, Evans DG, Eeles R, Paterson J, Brewer C; for the Epidemiological Study of Familial Breast Cancer
(EMBRACE), McGuffog L, Antoniou AC, Stoppa-Lyonnet D, Sinilnikova OM, Barjhoux L, Frenay M, Michel C,
Leroux D, Dreyfus H, Toulas C, Gladieff L, Uhrhammer N, Bignon YJ, Meindl A, Arnold N, Varon-Mateeva R,
Niederacher D, Preisler-Adams S, Kast K, Deissler H, Sutter C, Gadzicki D, Chenevix-Trench G, Spurdle AB,
Chen X, Beesley J; for the Kathleen Cuningham Foundation Consortium for Research into Familial Breast
Cancer (kConFab), Olsson H, Kristoffersson U, Ehrencrona H, Liljegren A; for the Swedish Breast Cancer
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
2
Biographical Sketch Format Page
Study, Sweden (SWE-BRCA), van der Luijt RB, van Os TA, van Leeuwen FE; for the Hereditary Breast and
Ovarian cancer group Netherlands (HEBON), Domchek SM, Rebbeck TR, Nathanson KL, Osorio A, Ramón Y
Cajal T, Konstantopoulou I, Benítez J, Friedman E, Kaufman B, Laitman Y, Mai PL, Greene MH, Nevanlinna
H, Aittomäki K, Szabo CI, Caldes T, Couch FJ, Andrulis IL, Godwin AK, Hamann U, Schmutzler RK; on behalf
of the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). Association of the Variants CASP8
D302H and CASP10 V410I with Breast and Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
Cancer Epidemiol Biomarkers Prev. 2010 Oct 26. [Epub ahead of print] PubMed PMID: 20978178.
13. Pertesi M, Konstantopoulou I, Yannoukakos D. Haplotype analysis of two recurrent genomic rearrangements
in the BRCA1 gene suggests they are founder mutations for the Greek population. Clin Genet. 2010 Aug 23.
doi: 10.1111/j.1399-0004.2010.01532.x. [Epub ahead of print] PubMed PMID: 20840220.
C. Research Support. List selected ongoing or completed (during the last three years) research projects (federal
and non-federal support). Begin with the projects that are most relevant to the research proposed in this
application. Briefly indicate the overall goals of the projects and your role (e.g. PI, Co-Principal Investigator,
Consultant) in the research project. Do not list award amounts or percent effort in projects.
1. Bilateral research program funded by GSRT with Serbia 2004-2006. BRCA1 & BRCA2 mutation analysis in Greek and Serbian &
Montenegro families with history of breast-ovarian cancer. PI.
Principal Investigator/Program Director (Last, First, Middle):
Konstantopoulou, Irene
Research Support
Title of Grant
BRCA1 & BRCA2 mutation analysis in Greek and Serbian & Montenegro families with history of breast-ovarian cancer
Role and % LOE
Supporting Agency (including name and address of grants officer)
Grant ID
50%
General Secretary for Research & Technology, Ministry of Development of
Greece Mesogeion Ave 14-18, 115 27 Athens Greece www.gsrt.gr
Performance Period
Amount of Funding
2004-2006
€35.000
Description (Include the goals and specific aims of the project)
PHS 398/2590 (Rev. 09/04, Reissued 4/2006)
Page
3
Biographical Sketch Format Page